Abstract
BackgroundNeoadjuvant chemotherapy (NAC) has clinically important outcome. Early evaluation of the treatment response is important to avoid unnecessary therapy in non-responders. MRI is the most sensitive imaging for monitoring NAC response. Aim of this studyIs to test the ability of DWI to detect early response to NAC. ResultsThe study was performed on 20 patients, proved pathologically to have invasive breast cancer. All patients underwent breast MRI before initiation of NAC, after one cycle and after completion of the NAC protocol. Regarding the mass size, results showed no significant change in maximum mass diameters occur after the 1st NAC cycle. Absolute value of the ADC show increase all along the treatment course which has no significant correlation with the pathological response. The relative increase ADC more than 20% calculated from subtraction of the pre-treatment ADCmean value from that after the first NAC, subdividing the result on the pre-treatment ADCmean value and multiply it by 100 reflected significantly on the pathological response (p value of 0.011). ConclusionADC value can predict responder from non-responder as early as after the first cycle of chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Egyptian Journal of Radiology and Nuclear Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
